Biolexis Therapeutics, an evolving champion in presenting best-in-class inflammation-targeted and next-generation metabolic therapies, proudly announced its selection for the two presentations at the 2nd Innovation in Obesity Therapeutics Summit. To present the company’s clinical development excellence, the Vice President of Clinical Development, Jeremiah Bearss, MD, PhD, has been selected to showcase at the popular global forum, elevating the development of the next generation of obesity treatment platforms.
This Summit brings known scientists and particular executives from Eli Lilly, Boehringer Ingelheim, Novo Nordisk and other company pioneers under one roof.
The dual selection of Dr Bearss represents Biolexis’s emerging reputation and consistent efforts as a scientific champion in the growing transformational obesity therapeutics landscape. This space is where next-generation ideas are considered on an urgent basis to identify the limitations of the latest weight-loss treatments.
Dr Bearss said, “The obesity space is at the modulation stage, while the latest GLP-1 therapies have met a commendable efficacy rate for weight loss. With this, we have measurably understood that the weight on a scale is not the book but only a part of the story. At Biolexis, we’re advancing the ideas that are beyond the promotion of weight loss, as are thought is also to improve and preserve muscle mass. This will change the perspective for the therapeutic success of patients.”
On Day 1, Dr Bearss will present Biolexis’s groundbreaking initiative, establishing the major pharmacologic strategies that recreate the metabolic impact of identifying the major mechanisms and endurance training. Mechanism includes activation of muscle-specific signalling pathways, inducing responsive-exercise gene programs and enhancement of mitochondrial function. This presentation’s title is ‘Integrating Exercise Mimetics to Mimic Physical Activity and Boost Metabolic Rate for Healthier Weight Loss’.
Further, for the panel discussion on the ‘Assessing Functional Readouts and Optimal Muscle-to-Fat Ratio to Redefine Success in Obesity Care’ topic, Dr Bearss will be joining senior company leaders to identify the crucial questions that are reframing the obesity therapeutics space. The questions might address or encompass the emergency move for the functional endpoints to meet muscle quality, endurance and strength, including weight.
It will also respond to the evolving scientific consensus regarding how much muscle loss is too excessive during obesity treatment. Additionally, the question of ‘how muscle-preserving therapeutics can uncover healthier and durable outcomes than weight mitigation alone’ will also be answerable.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
